Harper Molly

SEC Form 4 insider trading activity

Harper Molly has filed 5 SEC Form 4 filings (8 transaction rows) across 1 company, with disclosures dating back to 2025. 5 of those filings fall inside the rolling window. Most recent filing: Jul 17, 2026.

On the most recent filing, Harper Molly is listed as Director at CATALYST PHARMACEUTICALS, INC. Inside the rolling window, Harper Molly reported no open-market purchases and 1 open-market sale totaling $622K in CPRX.

Companies traded

Other insiders at CPRX

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$622K

reported sales (SEC code S)

Companies

1

in the rolling window

Source
CPRX
Harper Molly
Sale$622KDec 16SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Harper Molly made?

Harper Molly has filed 5 SEC Form 4 filings (8 transaction rows) across 1 company since 2025.

Which companies does Harper Molly trade?

Harper Molly has filed SEC Form 4 disclosures for 1 company, including CPRX.

When was Harper Molly's most recent SEC Form 4 filing?

Harper Molly's most recent SEC Form 4 filing on Tracefour is dated Jul 17, 2026.

What is Harper Molly's total buy and sell value in the current window?

Inside the rolling retention window, Harper Molly bought $0 and sold $622K based on SEC Form 4 filings.

What was Harper Molly's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 26,746 CPRX shares on 2025-12-12, worth $622K, per SEC Form 4 filings.